BRIDGE BLUEPRINT
Bridge Blueprint, How We Close Evidence Gaps
Translational Bridging is built for teams that need decision-ready evidence across the development lifecycle. We organize our work into Early and Late Translational Bridging so visitors can quickly identify where they are, what gaps exist, and what support is available. Our process involves:
-
Evidence gap diagnosis and stakeholder requirements map
-
Recommended study approach, endpoints, inclusion, and feasibility
-
Decision-ready evidence plan with timeline and key risks
-
Evidence-to-value package for partners, access, and adoption
FROM SIGNAL TO FEASIBILITY
Early Translational Bridging
Early Translational Bridging discerns proof-of-concept viability and first-in-human readiness. We compile robust early evidence to support confident go/no-go and program design decisions. Early Translational Bridging includes:
-
Feasibility and evidence gap assessment
-
Early endpoint strategy and validation plan
-
Study blueprint for bridging (design, cohorts, measures)
-
Readiness package for partnering discussions
FROM APPROVAL TO REAL-WORLD APPLICATION
Late Translational Bridging
Late Translational Bridging concentrates Phase IV and post-approval learning where it matters most: safety, effectiveness, access, and outcomes across populations. We support surveillance and evidence generation that can enable repurposing, expansion, or redevelopment for new indications. Late Translational Bridging includes:
-
Post-approval learning agenda and Phase IV strategy
-
Observational study blueprint (registries, RWE, surveillance)
-
Signal detection and monitoring plan
-
Evidence package for expansion, access, and adoption
EVIDENCE-TO-VALUE STACK
Built for Regulators, Payers, Providers, and Partners
HEOR (Health Economics and Outcomes Research)
-
Outcomes measurement strategy and value evidence planning
-
Comparative effectiveness framing and patient-reported outcomes
-
Health resource utilization insights to support decision points
Health Economics and Reimbursement
-
Payer-relevant evidence strategy aligned to real-world decision makers
-
Coverage and reimbursement considerations integrated into evidence design
-
Value story development grounded in measurable outcomes
SDoH and Equity Analytics
-
Barrier identification and segmentation to reflect real populations
-
Community engagement approaches and equity endpoints
-
Outcome reporting that shows who benefits and where gaps persist
Costing and Affordability Models
-
Budget impact and cost-effectiveness models to support access and uptake
-
Patient affordability models with transparent assumptions and populations
-
Evidence designed for the end in mind: patients, providers, payers, regulators, and communities
Bridge Supports (Cross-Cutting Components)
Rubix LS designs evidence with the end in mind, built for real decisions and real-world outcomes.
As the Health Outcomes Architect Company, we turn complex health challenges into decision-grade research programs.
Real-World Studies & Trials
Explore ongoing Rubix LS studies to see our commitment to transparency, active research leadership, and closing real-world evidence gaps.
DEVELOPMENT STAGE
Project Panacea
Breast Cancer
Project ARCHNGL
Neurodegeneration
Project Aegis
Autoimmune Disorders
Contract Research Organization
Rubix LS delivers full-spectrum CRO services designed to accelerate clinical development with precision and flexibility. Our teams integrate regulatory expertise, real-world data, and inclusive trial design to drive faster, more impactful research outcomes.
Federal Projects
Rubix LS is a trusted partner for federal agencies seeking agile, responsive contract research solutions. We bring cross-disciplinary teams and life sciences innovation to the front lines of federally funded public health projects.